Strange: Bullish RARE Analysts Actually See -8.58% Downside

An image of a tablet with a stock chart on the display
Credit: Shutterstock photo

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Ultragenyx Pharmaceutical Inc (Symbol: RARE). The average 12-month price target for RARE - averaging the work of 15 analysts - reveals an average price target of $72.53/share. That's a whopping -8.58% below where RARE has been trading recently at $79.34/share. With this kind of downside potential (should RARE fall to that price target), one might expect to see a high concentration of "hold" or even "sell" ratings on the stock. Yet, take a look at the bullishness:

Recent RARE Analyst Ratings Breakdown
Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 12 13 13 13
Buy ratings: 1 1 1 1
Hold ratings: 1 2 2 3
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 1.21 1.31 1.31 1.41

The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.21 for RARE leans strongly towards the bullish end of the spectrum, yet the RARE price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at Ultragenyx Pharmaceutical Inc. Of course, the average price target is just that - a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $95.00. And then on the other side of the spectrum one analyst has a target as low as $57.00. The standard deviation is $8.584.

But the whole reason to look at the average in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes - much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with RARE trading so far above that average target price of $72.53/share, the -8.58% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good "signal" to investors in RARE to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for Ultragenyx Pharmaceutical Inc. This article used data provided by Zacks Investment Research via . Get the latest Zacks research report on RARE - FREE .

The Top 25 Broker Analyst Picks of the S&P 500 »

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

    BNK Invest

    BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.

    Learn More